Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744187 | 0.88 | CRBN (0.32) | CRBNDDB1 | |
| SCHEMBL3745330 | 0.88 | CRBN (0.41) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL3755200 | 0.84 | HTR2A (0.36) | CRBNDDB1 | |
| SCHEMBL476941 | 0.81 | CRBN (0.44) | CRBNDDB1ALDH1A1KDM4E | |
| SCHEMBL30001714 | 0.81 | CRBN (0.44) | CRBNDDB1ALDH1A1KDM4E | |
| SCHEMBL3749207 | 0.81 | DDB1 (0.52) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL3738115 | 0.81 | CRBN (0.43) | CRBNDDB1HSD17B10CASP3 | |
| SCHEMBL3752341 | 0.75 | PDK1 (0.33) | CRBNDDB1TYR | |
| SCHEMBL3738089 | 0.74 | CRBN (0.47) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL3803912 | 0.72 | DDB1 (0.52) | CRBNDDB1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834033-B2 | Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine | CELGENE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-7005438-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-6762195-B2 | TREATING DISEASES MEDIATED BY TUMOR NECROSIS FACTOR; INHIBIT ANGIOGENESIS AND TREATMENT OF CANCER, INFLAMMATORY, AND AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | disclosed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4232/4885DDB1 2659/4885ALDH1A1 237/4885 |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4077/4885DDB1 2244/4885ALDH1A1 169/4885 |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4232/4885DDB1 2659/4885ALDH1A1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.